医薬品安全性監視及び薬物安全性ソフトウェアの世界市場...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 15
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 21
2.1.2.2 Key industry insights 22
2.1.2.3 Breakdown of primaries 22
2.2 MARKET SIZE ESTIMATION 23
2.2.1 BOTTOM-UP APPROACH 23
2.2.2 TOP-DOWN APPROACH 24
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.4 RESEARCH ASSUMPTIONS 26
2.4.1 ASSUMPTIONS 26

3 EXECUTIVE SUMMARY 27
3.1 INTRODUCTION 27
3.2 CURRENT SCENARIO 28
3.3 FUTURE OUTLOOK 29
3.4 CONCLUSION 30

4 PREMIUM INSIGHTS 31
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET 31
4.2 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY 32
4.3 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER 33
4.4 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION 34

5 MARKET OVERVIEW 35
5.1 INTRODUCTION 36
5.2 MARKET SEGMENTATION 36
5.2.1 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET,
BY FUNCTIONALITY 36
5.2.2 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET,
BY DELIVERY MODE 37
5.2.3 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET,
BY END USER 37
5.3 MARKET DYNAMICS 38
5.3.1 KEY MARKET DRIVERS 38
5.3.1.1 Intensification of drug safety regulations by government authorities 38
5.3.1.2 Heavy clinical R&D expenditure by the pharmaceutical industry 39
5.3.1.3 Benefits offered by PV solutions—reduced cost and time involved in clinical trial processes 39
5.3.1.4 Government grants to support clinical trials 39
5.3.1.5 Large investments in healthcare IT by governments from mature as well as developing nations 40
5.3.2 KEY MARKET RESTRAINTS 41
5.3.2.1 Dearth of healthcare IT professionals 41
5.3.2.2 Cultural differences and language barriers 42
5.3.3 KEY MARKET OPPORTUNITIES 42
5.3.3.1 Cloud technology provides opportunities for industry players 42
5.3.3.2 Emerging markets to offer high growth opportunities 42
5.3.4 KEY MARKET CHALLENGES 43
5.3.4.1 Lack of standardization and harmonization of drug safety regulations 43
5.3.4.2 Low adoption of pharmacovigilance solutions in the least developed countries 43

6 INDUSTRY INSIGHTS 45
6.1 INTRODUCTION 45
6.2 PORTER’S FIVE FORCES ANALYSIS 45
6.2.1 THREAT FROM NEW ENTRANTS 46
6.2.2 THREAT FROM SUBSTITUTES 47
6.2.3 BARGAINING POWER OF SUPPLIERS 47
6.2.4 BARGAINING POWER OF BUYERS 48
6.2.5 INTENSITY OF COMPETITIVE RIVALRY 48
6.3 INDUSTRY TRENDS 49
6.3.1 STRONG FOCUS ON NEW PRODUCT LAUNCHES 49
6.3.2 GROWING MARKET PREFERENCE FOR CLOUD-BASED PLATFORMS 49
 
7 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY 50
7.1 INTRODUCTION 51
7.2 ADVERSE EVENT REPORTING SOFTWARE 52
7.3 DRUG SAFETY AUDIT SOFTWARE 53
7.4 FULLY INTEGRATED SOFTWARE 53
7.5 ISSUE TRACKING SOFTWARE 54

8 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE 55
8.1 INTRODUCTION 56
8.2 ON-PREMISE DELIVERY MODE 57
8.3 ON-DEMAND/CLOUD-BASED (SAAS) DELIVERY MODE 57

9 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER 59
9.1 INTRODUCTION 60
9.2 CONTRACT RESEARCH ORGANIZATIONS (CROS) 61
9.3 PHARMA AND BIOTECH COMPANIES 62
9.4 BUSINESS PROCESS OUTSOURCING (BPO) FIRMS 63
9.5 OTHER PHARMACOVIGILANCE SERVICE PROVIDERS 64

10 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION 66
10.1 INTRODUCTION 67
10.2 NORTH AMERICA 68
10.2.1 U.S. 71
10.2.2 CANADA 73
10.3 EUROPE 75
10.3.1 GERMANY 78
10.3.2 U.K. 80
10.3.3 FRANCE 81
10.3.4 REST OF EUROPE 83
10.4 ASIA-PACIFIC 84
10.4.1 JAPAN 87
10.4.2 CHINA 89
10.4.3 INDIA 90
10.4.4 REST OF ASIA-PACIFIC 92
10.5 ROW (REST OF THE WORLD) 93
10.5.1 LATIN AMERICA 95
10.5.2 MIDDLE EAST 97
10.5.3 AFRICA 98

11 COMPETITIVE LANDSCAPE 101
11.1 OVERVIEW 101
11.2 MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014 102
11.3 COMPETITIVE SITUATION AND TRENDS 103
11.4 RECENT DEVELOPMENTS 104
11.4.1 NEW PRODUCT LAUNCHES 104
11.4.2 ACQUISITIONS, PARTNERSHIPS, AND AGREEMENTS 105
11.4.3 NEW SERVICE LAUNCHES AND SERVICE EXPANSIONS 106
11.4.4 GEOGRAPHICAL EXPANSIONS 106
11.4.5 OTHER DEVELOPMENTS 107

12 COMPANY PROFILES 108
12.1 INTRODUCTION 108
12.2 ORACLE CORPORATION 108
12.2.1 BUSINESS OVERVIEW 108
12.2.2 PRODUCT PORTFOLIO 109
12.2.3 KEY STRATEGY 109
12.2.4 RECENT DEVELOPMENTS 109
12.2.5 SWOT ANALYSIS 110
12.3 ARISGLOBAL LLC 111
12.3.1 BUSINESS OVERVIEW 111
12.3.2 PRODUCTS & SERVICES 111
12.3.3 KEY STRATEGY 112
12.3.4 RECENT DEVELOPMENTS 112
12.3.5 SWOT ANALYSIS 114
12.4 EXTEDO GMBH 115
12.4.1 BUSINESS OVERVIEW 115
12.4.2 PRODUCTS & SERVICES 115
12.4.3 KEY STRATEGY 115
12.4.4 SWOT ANALYSIS 116
12.5 AB-CUBE 117
12.5.1 BUSINESS OVERVIEW 117
12.5.2 PRODUCT & SERVICES 117
12.5.3 KEY STRATEGY 117
12.6 ENNOV SOLUTIONS, INC. 118
12.6.1 BUSINESS OVERVIEW 118
12.6.2 PRODUCTS & SERVICES 118
12.6.3 KEY STRATEGY 118
12.6.4 RECENT DEVELOPMENTS 119
 
12.7 ONLINE BUSINESS APPLICATIONS, INC. 120
12.7.1 BUSINESS OVERVIEW 120
12.7.2 PRODUCTS & SERVICES 120
12.7.3 KEY STRATEGY 120
12.7.4 RECENT DEVELOPMENTS 121
12.8 SARJEN SYSTEMS PVT. LTD. 122
12.8.1 BUSINESS OVERVIEW 122
12.8.2 PRODUCTS & SERVICES 122
12.8.3 KEY STRATEGY 123
12.9 SPARTA SYSTEMS, INC. 124
12.9.1 BUSINESS OVERVIEW 124
12.9.2 PRODUCTS & SERVICES 124
12.9.3 KEY STRATEGY 124
12.9.4 RECENT DEVELOPMENTS 125
12.10 UMBRA GLOBAL, LLC 127
12.10.1 BUSINESS OVERVIEW 127
12.10.2 PRODUCTS & SERVICES 127
12.10.3 KEY STRATEGY 127
12.10.4 RECENT DEVELOPMENTS 128
12.11 UNITED BIOSOURCE CORPORATION (AN EXPRESS SCRIPTS COMPANY) 129
12.11.1 BUSINESS OVERVIEW 129
12.11.2 SERVICES PORTFOLIO 129
12.11.3 KEY STRATEGY 129
12.11.4 RECENT DEVELOPMENTS 129

13 APPENDIX 130
13.1 INSIGHTS OF INDUSTRY EXPERTS 130
13.2 DISCUSSION GUIDE 131
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 134
13.4 AVAILABLE CUSTOMIZATIONS 134
13.5 RELATED REPORTS 135